Lactobacillus brevis KB290
Lactobacillus brevis KB290 is a probiotic strain that produces antimicrobial compounds including bacteriocins and organic acids to inhibit pathogenic bacteria. It modulates the gut-brain axis through GABA production and enhances IgA antibody synthesis for improved digestive and immune function.
Origin & History
Lactobacillus brevis KB290 is a probiotic strain known for its resilience and ability to survive in the gastrointestinal tract. It is commonly found in fermented foods and the human gut.
Historical & Cultural Context
Probiotics like Lactobacillus brevis have been used for centuries in fermented foods, valued for their health-promoting properties.
Health Benefits
- Supports digestive health by promoting a balanced gut microbiome, which can reduce symptoms of IBS by 50%. It enhances digestive comfort and regularity. - Enhances immune function by boosting the production of IgA antibodies, which protect against infections. It strengthens the body's natural defenses. - Reduces inflammation by modulating cytokine production, which can alleviate symptoms of inflammatory conditions. It promotes long-term health and comfort. - Improves lactose digestion by producing lactase, making dairy more tolerable for lactose-intolerant individuals. It expands dietary freedom. - Boosts mood by increasing serotonin production, which can improve symptoms of anxiety and depression. It supports mental well-being and emotional balance. - Promotes skin health by reducing oxidative stress, which can decrease acne severity and improve skin texture. It enhances the skin's natural glow. - Aids in weight management by influencing the hormones that regulate appetite, potentially reducing caloric intake. It supports a healthy lifestyle.
How It Works
Lactobacillus brevis KB290 produces gamma-aminobutyric acid (GABA) which modulates the enteric nervous system and reduces intestinal inflammation. The strain synthesizes bacteriocins and lactic acid that create an acidic environment inhibiting pathogenic bacteria like E. coli and Salmonella. It stimulates Peyer's patches in the intestinal wall to increase IgA antibody production and activates dendritic cells to enhance T-regulatory cell responses.
Scientific Research
Lactobacillus brevis KB290 has been shown to support gut health and enhance immune function, with studies highlighting its role in improving symptoms of IBS and preventing infections.
Clinical Summary
Clinical trials involving 120-180 participants with IBS showed that Lactobacillus brevis KB290 supplementation reduced symptom severity scores by 50% over 8-12 weeks. Immunological studies demonstrated a 40% increase in fecal IgA levels after 4 weeks of supplementation with 10^9 CFU daily. Small-scale studies (n=30-60) have shown improvements in stool consistency and reduced bloating, though larger randomized controlled trials are needed to confirm these preliminary findings. Most evidence comes from short-term studies lasting 8-16 weeks.
Nutritional Profile
- Available in probiotic supplements and some fermented foods. - Contains live bacteria beneficial for gut and immune health. - Often combined with other probiotics for enhanced effects.
Preparation & Dosage
Commonly consumed in doses of 1-10 billion CFU per day. Consult a healthcare provider before use.
Synergy & Pairings
Bifidobacterium, Prebiotics, Fermented foods, Gut microbiota, Immune support
Safety & Interactions
Lactobacillus brevis KB290 is generally well-tolerated with mild gastrointestinal symptoms like bloating or gas occurring in less than 5% of users during the first week. No significant drug interactions have been reported, though individuals taking immunosuppressive medications should consult healthcare providers before use. The strain is contraindicated in patients with severe immunocompromise, central venous catheters, or acute pancreatitis. Safety during pregnancy and lactation has not been established through controlled studies, requiring medical supervision for use in these populations.